Skip to content Skip to navigation

SOLD OUT: Biotechnology and its Impact on the Future of Greater Boston

Monday, May 21, 2018 - 5:30pm to 7:00pm

This event is SOLD OUT. You are welcome to register on our wait list.

Reception to follow
Registration is requested

Biotechnology and its Impact on the Future of Greater Boston

Dr. Adam Koppel, Dr. David Meeker, Dr. Craig C. Mello, and Carl Zimmer

Join us for a panel discussion that will explore exciting developments in the life sciences. The latest trends in gene therapy, gene editing, and RNA interference--to name a few subjects--will be examined. The panelists will also trace the journey of consumer and clinical products from the spark of an idea to product-testing in the lab. Other questions for discussion include: What are current trends in the life sciences and how can they be extended into the future? And what impact will those trends have on the greater Boston area? Come learn about this fascinating field and its impact on both an individual and societal level.

Carl Zimmer, esteemed science writer for the New York Times, will serve as moderator for the panel comprised of three outstanding speakers: Nobel Laureate Dr. Craig C. Mello representing academic research, Dr. Adam Koppel of Bain Capital Life Science Ventures representing venture capital, and Dr. David Meeker of KSQ Therapeutics, formerly of Genzyme/Sanofi, representing industry.

Dr. Adam K. Koppel, panelist, rejoined Bain Capital in 2016 as Managing Director of the Bain Capital Biosciences Fund. He had initially joined Bain Capital Public Equity in 2003 where he was a leader within the healthcare sector until mid-2014. From mid-2014 to mid-2016, Dr. Koppel was at Biogen where he served as EVP of Corporate Development and Chief Strategy Officer. Prior to initially joining Bain Capital in 2003, he was an Associate Principal at McKinsey & Co in New Jersey, where he served a variety of healthcare companies.

Dr. Koppel received an MD and PhD in neuroscience from the University of Pennsylvania School of Medicine. He also earned an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. Dr. Koppel graduated with an AB and AM in History and Science from Harvard University.

Dr. David Meeker, panelist, joined KSQ from Sanofi, where he was a member of the executive committee and Head of Sanofi-Genzyme. He previously served as President and CEO of Genzyme (a Sanofi company) following the merger of Genzyme and Sanofi. Dr. Meeker assumed responsibility of the rare disease unit and the launch of the company’s new multiple sclerosis franchise, and he was given responsibility for the full specialty-care portfolio of Sanofi, adding the oncology and immunology portfolios.

Dr. Meeker currently serves as chairman of the board of Rhythm Pharmaceuticals and Trevl Therapeutics, and is a member of the board of Myokardia. He also serves on the boards of the Biomedical Science Careers Program and the Network for Excellence in Health Innovation. He received his MD from the University of Vermont Medical School and he completed the Advanced Management Program at Harvard Business School.

Dr. Craig C. Mello, panelist, investigates how cells use short segments of genetic code to find and regulate matching information and how organisms use these search mechanisms to regulate, share, and propagate genetic information. His pioneering research on RNA interference (RNAi), in collaboration with Dr. Andrew Fire, has been recognized with numerous awards culminating with the prestigious 2006 Nobel Prize in Physiology or Medicine.

Dr. Mello earned his BSc degree in biochemistry from Brown University and his PhD from Harvard University. Dr. Mello joined the University of Massachusetts Medical School faculty in 1995 and is now the Blais University Chair in Molecular Medicine and distinguished professor of molecular medicine and cell and developmental biology. Dr. Mello has authored or co-authored more than fifty scientific articles that have appeared in journals such as Science, Current Biology, Genes & Development, Cell Cycle, Cell, and Developmental Biology, among others.

Carl Zimmer, moderator, writes books, articles, essays, and blog posts in which he reports from the frontiers of biology. Since 2013 he has been a columnist at the New York Times, where his column “Matter” appears each week. He is a popular speaker and frequently appears on radio programs such as Radiolab and This American Life.

Mr. Zimmer has written 13 books about science, including She Has Her Mother's Laugh: The Powers, Perversions, and Potential of Heredity, which will be published in May 2018. He has also written two widely praised textbooks and hundreds of articles for the New York Times and magazines such as National Geographic, Time, Scientific American, Science, and Popular Science. Mr. Zimmer’s work has been recognized with a number of awards, including the Stephen Jay Gould Prize in 2016, awarded annually by the Society for the Study of Evolution to recognize individuals whose sustained efforts have advanced public understanding of evolutionary science.

This event is sponsored by:




To register, follow the registration button on the right. If you would prefer your information to pre-populate, log in to your My Athenæum Profile. To log in to your My Athenæum Profile click on the profile icon found in the upper right corner of each page on our website.

If you do not yet have a profile, select “New User? Create an account” on the Profile Login page. Members create their own accounts; a username and password are not assigned when you join the Athenæum.

Assistive Listening Devices image

Auto-generated captions are available for most virtual programs. To request live captioning or other accommodations, please contact Hannah Weisman at or 617-720-7617 at least four business days prior to the event.